URC102 clinical trials
Also written URC102.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2013
How each study uses URC102 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- URC102
- 4
Studies by the year they started
5 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses URC102 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal ImpairmentCompletedPhase 1JW PharmaceuticalNCT05198778Written as URC102
- Phase 1 Study(Additional) of URC102 in Healthy SubjectsCompletedPhase 1JW PharmaceuticalNCT02524678Written as URC102
- Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout PatientsCompletedPhase 2JW PharmaceuticalNCT02290210Written as URC102 0.25mg
- Phase 1 Study of URC102 in Healthy SubjectsCompletedPhase 1JW PharmaceuticalNCT01953497Written as URC102
- Study of URC102 to Assess the Safety and Efficacy in Gout PatientsCompletedPhase 2JW PharmaceuticalNCT02557126Written as URC102